전신성 홍반성 낭창 환자에서 유리형 Fas 단백질에 대한 연구 = Soluble Fas Expression in Systemic Lupus Erythematosus

다국어 초록 (Multilingual Abstract)

Objective: To investigate soluble Fas(sFas) protein in the sera of patients with systemic lupus erythematosus (SLE). Methods: sFas protein was measured by sandwich ELISA method in the sera of 30 patients with SLE (mean age: 27.4±8.46, F:M=29:1) and 11 patients with fibromyalgia (mean age 35.8±11.5, F:M-11:0) as a control group. Results: sFas was elevated in 6 (20%) patients of SLE and 1 (9%) of patients with fibromyalgia (p=0.41). sFas level was correlated with a shorter duration, lower dosage of systemic steroid and higher disease activity in patients with elevated sFas levlel compared to patients with normal serum levels of sFas. All patients with elevated sFas had been diagnosed with SLE for less than 1 month. Fifty % (6 out of 12) patients with SLE for less than 1 month showed elevated sFas in serum. There was no difference of in the age between patients with elevated and normal levels of sFas. Conclusion: These data indicate that elevated sera levels of sFas was associated with the early active phase of disease in some patients with SLE and may play a role in defective apoptosis.